Using Patent Data to Assess the Value of Pharmaceutical Innovation

被引：8
|
作者：
Kesselheim, Aaron S. [1 ,2 ]
Avorn, Jerry [1 ,2 ]
机构：
[1] Harvard Univ, Sch Med, Cambridge, MA 02138 USA
[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA
来源：
JOURNAL OF LAW MEDICINE & ETHICS | 2009年 / 37卷 / 02期
关键词：
CITATIONS; COST; UNIVERSITIES; TECHNOLOGY; EXPERIENCE; KNOWLEDGE; DRUGS;
D O I：
10.1111/j.1748-720X.2009.00364.x
中图分类号：
B82 [伦理学（道德学）];
学科分类号：
摘要：
Though many more patents emerge from industry sources, drug-related patents generated in the non-profit setting appear to have greater importance than patents arising from the commercial sector, which helps demonstrate the value non-profit research institutions can have in driving drug development.
引用
收藏
页码：176 / 183
页数：8
相关论文
共 50 条
12345